Stronger. Together.

Collaboration is a cornerstone of Apogee’s growth strategy. Apogee actively seeks partnerships with biotechnology companies, academic institutions, and other organizations that share its commitment to innovation in women’s health therapeutics and diagnostics. Apogee focuses on opportunities where it can be an active, value‑adding partner. Apogee prefers preclinical assets; under the right circumstances it will consider later‑stage or larger arrangements when the data and the business case are compelling.

Apogee invites potential partners to explore a range of collaboration opportunities, including:

  • In-Licensing & Asset Acquisition: Apogee welcomes in‑licensing of promising drug candidates, patented technologies, or novel IP in its core focus areas. Apogee prioritizes preclinical assets (e.g., hit‑to‑lead, lead optimization, or candidate‑selection) while evaluating later‑stage programs where Apogee can add material value, and the evidence package is strong. For compelling therapeutic or diagnostic assets in endometriosis, adenomyosis, or the ECS, Apogee brings translational R&D expertise and disciplined resources to advance them. Apogee also evaluates acquiring early‑stage assets or companies that complement its pipeline and align with its strategy.

  • Joint Ventures & Co-Development: Apogee is open to co‑development agreements, joint ventures, and research collaborations where each party brings unique capabilities. For example, Apogee may partner with academic laboratories on translational research or co‑create new companies around synergistic programs, Apogee engages hands-on across the science and operations to drive progress efficiently and share in its success.

  • Strategic Investment & Partnerships: Backed by a healthcare‑focused investment firm, Apogee structures right-sized partnerships – equity investments, option agreements, or M&A – when the program closely aligns with the Apogee mission and it can play an active role. Apogee deploys capital pragmatically and does not seek passive financial positions; the goal is to accelerate programs where Apogee’s capabilities make a clear difference.

Beyond these scientific criteria, Apogee also considers strategic factors to maximize the impact of its work. Apogee evaluates the intellectual property landscape and competitive environment for each potential program, favoring opportunities where it can secure strong IP positions and where there is relatively limited direct competition. By aligning robust science with strategic positioning, Apogee ensures that its efforts are not only scientifically sound but also poised to deliver unique medicines that stand out in the biotechnology space.